International Orthopaedics

, Volume 38, Issue 1, pp 183–192 | Cite as

Association of systemic and intra-articular osteoclastogenic potential, pro-inflammatory mediators and disease activity with the form of inflammatory arthritis

  • Marina Ikić
  • Zrinka Jajić
  • Elvira Lazić
  • Sanja Ivčević
  • Frane Grubišić
  • Ana Marušić
  • Nataša Kovačić
  • Danka Grčević
Original Paper
First Online:
Received:
Accepted:

Abstract

Purpose

We aimed to assess osteoclastogenic potential of peripheral blood mononuclear cells (PBMC) and synovial fluid-derived mononuclear cells (SFMC) in different forms of arthritis and to correlate it with inflammatory mediators within intra-articular and circulatory compartments.

Methods

Paired PBMC and SFMC samples of patients with rheumatoid arthritis (RA; n = 10) and psoriatic arthritis (PsA; n = 10), and PBMC of healthy controls were cultured to assess osteoclastogenic potential by the number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts (OCs) and expression of OC-related genes (receptor activator of nuclear factor-κΒ (RANK), cFMS, and TRAP). Osteoclastogenesis was correlated with the arthritis-related inflammatory indicators in serum and synovial fluid (SF).

Results

Number of OCs differentiated from PBMC was significantly higher in RA and PsA compared with control, with RA having more OCs compared with PsA. There was no difference in SFMC OC number between arthritic patients, but RANK expression in OCs differentiated from SFMC was higher in PsA compared with RA. SF of PsA patients more potently induced OC differentiation from control CD3-CD19-CD56-CD11b+CD115+ PBMC compared with RA, paralleled with higher RANK-ligand expression in PsA SFMC. Positive correlations of OC number with erythrocyte sedimentation rate, serum level of CCL2, and PBMC gene expression of interleukin-18 and Fas-ligand were observed.

Conclusion

Osteoclastogenic potential is systemically enhanced in patients with RA, paralleled by disordered systemic and local expression of proinflammatory mediators, whereas PsA involves specific deregulation in RANKL/RANK axis. Our study reveals arthritis-specific mediators associated with the form of arthritis, indicating clinical relevance for diagnosis and treatment.

Keywords

Rheumatoid arthritis Psoriatic arthritis Osteoclasts Cytokines Inflammation Bone loss Peripheral blood Synovial fluid 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by grants from the Croatian Ministry of Science, Education and Sports (108-1080229-0140, 108-1080229-0142, and 108-1080229-0341).

We thank Prof. Vedran Katavic for critically revising the manuscript and Mrs. Katerina Zrinski-Petrovic for her technical assistance.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

264_2013_2121_MOESM1_ESM.docx (17 kb)
Supplementary Table 1 (DOCX 17.3 kb)
264_2013_2121_MOESM2_ESM.docx (14 kb)
Supplementary Table 2 (DOCX 14 kb)

References

  1. 1.
    Lari R, Kitchener PD, Hamilton JA (2009) The proliferative human monocyte subpopulation contains osteoclast precursors. Arthritis Res Ther 11:R23PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Roux C (2011) Osteoporosis in inflammatory joint diseases. Osteoporos Int 22:421–433PubMedCrossRefGoogle Scholar
  3. 3.
    Grčević D, Lukić IK, Kovačić N, Ivčević S, Katavić V, Marušić A (2006) Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin Exp Immunol 146:146–158PubMedCentralPubMedGoogle Scholar
  4. 4.
    Colucci S, Brunetti G, Cantatore FP et al (2007) Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol 212:47–55PubMedCrossRefGoogle Scholar
  5. 5.
    Dalbeth N, Pool B, Smith T et al (2010) Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 12:R164PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Lorenzo J, Horowitz M, Choi Y (2008) Osteoimmunology: interactions of the bone and immune system. Endocr Rev 29:403–440PubMedCrossRefGoogle Scholar
  7. 7.
    Grčević D, Jajić Z, Kovačić N, Lukić IK, Velagić V, Grubišić F, Ivčević S, Marušić A (2010) Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol 37:246–256PubMedCrossRefGoogle Scholar
  8. 8.
    Schett G, Saag KG, Bijlsma JW (2010) From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 69:1415–1419PubMedCrossRefGoogle Scholar
  9. 9.
    Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N (2006) Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther 8:R152PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821–831PubMedCentralPubMedGoogle Scholar
  11. 11.
    Bugatti S, Manzo A, Bombardieri M, Vitolo B, Humby F, Kelly S, Montecucco C, Pitzalis C (2011) Synovial tissue heterogeneity and peripheral blood biomarkers. Curr Rheumatol Rep 13:440–448PubMedCrossRefGoogle Scholar
  12. 12.
    Finzel S, Englbrecht M, Engelke K, Stach C, Schett G (2011) A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis 70:122–127PubMedCrossRefGoogle Scholar
  13. 13.
    Miyamoto K, Ninomiya K, Sonoda KH et al (2009) MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner. Biochem Biophys Res Commun 383:373–377PubMedCrossRefGoogle Scholar
  14. 14.
    Kim MS, Magno CL, Day CJ, Morrison NA (2006) Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP-1 and RANTES. J Cell Biochem 97:512–518PubMedCrossRefGoogle Scholar
  15. 15.
    Kim MS, Day CJ, Morrison NA (2005) MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 280:16163–16169PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y (2001) Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276:563–568PubMedCrossRefGoogle Scholar
  17. 17.
    Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP (2010) Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther 12:R29PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Toussirot E (2012) The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 11:159–168PubMedCrossRefGoogle Scholar
  19. 19.
    Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025–4031PubMedGoogle Scholar
  20. 20.
    Morita Y, Kitaura H, Yoshimatsu M, Fujimura Y, Kohara H, Eguchi T, Yoshida N (2010) IL-18 inhibits TNF-alpha-induced osteoclastogenesis possibly via a T cell-independent mechanism in synergy with IL-12 in vivo. Calcif Tissue Int 86:242–248PubMedCrossRefGoogle Scholar
  21. 21.
    Zhang W, Cong XL, Qin YH, He ZW, He DY, Dai SM (2013) IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis. Inflammation 36:103–109PubMedCrossRefGoogle Scholar
  22. 22.
    Dai SM, Nishioka K, Yudoh K (2004) Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Ann Rheum Dis 63:1379–1386PubMedCrossRefGoogle Scholar
  23. 23.
    Park H, Jung YK, Park OJ, Lee YJ, Choi JY, Choi Y (2005) Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 175:7193–7201PubMedGoogle Scholar
  24. 24.
    Peng SL (2006) Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford) 45:26–30CrossRefGoogle Scholar
  25. 25.
    Dickerson TJ, Suzuki E, Stanecki C, Shin HS, Qui H, Adamopoulos IE (2012) Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6. J Autoimmun 39:36–76CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Marina Ikić
    • 1
    • 2
  • Zrinka Jajić
    • 3
  • Elvira Lazić
    • 4
  • Sanja Ivčević
    • 1
  • Frane Grubišić
    • 3
  • Ana Marušić
    • 5
  • Nataša Kovačić
    • 1
  • Danka Grčević
    • 1
    • 6
  1. 1.Laboratory for Molecular ImmunologyUniversity of Zagreb School of MedicineZagrebCroatia
  2. 2.Department of Clinical Immunology and RheumatologyUniversity Hospital “Holy Ghost”, University of Zagreb School of MedicineZagrebCroatia
  3. 3.Department of Rheumatology, Physical Medicine and RehabilitationClinical Hospital Center “Sisters of Mercy”, University of Zagreb School of MedicineZagrebCroatia
  4. 4.Department of Dermatology and VenereologyGeneral Hospital “Dr. Ivo Pedišić”SisakCroatia
  5. 5.Department of Research in Biomedicine and HealthUniversity of Split School of MedicineSplitCroatia
  6. 6.Department of Physiology and ImmunologyUniversity of Zagreb School of MedicineZagrebCroatia

Personalised recommendations